Clinical trials: Endometrial Carcinoma
Breast Cancer Metastatic, Endometrial Cancer Stage IV
Plant-Based Nutrition for Breast or Endometrial Cancer
This is a randomized controlled trial of a whole food, plant-based (WFPB) dietary intervention among women with metastatic breast or endometrial cancer.
- Trial name
- BEND-MBEC (NCT07189702)
- Testing
- Control, Whole Food, Plant-Based Diet with Behavioral Education and Support
- Volunteers
- 60 people
- Sponsor
- University of Rochester
ERAS, Gynecologic Cancer
Adherence and Compliance to ERAS in Gynecological Surgery
The aim of the study is to investigate the association between early non-compliance to ERAS in postoperative day 2 (POD2) with the rate of postoperative complications.
- Conditions
- ERAS, Gynecologic Cancer, Post Operative Pain, Ovarian Cancer
- Trial name
- ERASGYNBS002 (NCT05738902)
- Testing
- Assessment of compliance to ERAS.
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APOLLO (NCT07909031)
- Testing
- CR-002
- Where
- 3 sites in United States
- Volunteers
- 219 people
- Sponsor
- Crescent Biopharma, Inc.
Endometrial Cancer
Telephone Follow-up After Treatment for Endometrial Cancer
The aim of this study is to investigate the feasibility, safety and accuracy of a telephone follow-up for women previously treatment for endometrial cancer.
- Trial name
- TEACUP (NCT01610375)
- Testing
- Telephone Follow-up
- Where
- Australia
- Volunteers
- 149 people
- Sponsor
- Queensland Centre for Gynaecological Cancer
Endometrial Cancer, Gastrointestinal Stromal Tumor
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
RATIONALE: STI571 may interfere with the growth of cancer cells and may be an effective treatment for soft tissue sarcoma. PURPOSE: Phase I/II trial to study the effectiveness of STI571 in treating patients who have recurrent or…
- Conditions
- Endometrial Cancer, Gastrointestinal Stromal Tumor, Ovarian Cancer, Sarcoma
- Trial name
- NCT00006357
- Testing
- imatinib mesylate
- Where
- 16 sites in Belgium, Denmark and 3 more
- Volunteers
- 91 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Endometrial Cancer, Extreme Obesity
Transvaginal Natural Orifice Endoscopic Surgery for Extremely Obese Patients With Early-stage Endometrial Cancer
The aim of this study is to investigate the feasibility and efficacy of the v-NOTES approach for extremely obese patients with early-stage type 1 endometrial cancer.
- Trial name
- NCT04240730
- Testing
- Transvaginal natural orifice endoscopic surgery for endometrial cancer staging
- Where
- Turkey (Türkiye)
- Volunteers
- 6 people
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
Endometrial Cancer Stage I, Endometrial Cancer Stage II
Cost-utility of Ambulatory Surgery in the Management of Endometrial Cancer(AMBU-ENDO)
To date, cost-utility, safety, and feasibility of ambulatory surgery versus traditional pathway in the management of endometrial cancer have never been prospectively assessed.
- Trial name
- AMBU-ENDO (NCT03580421)
- Testing
- ambulatory surgery, standard surgery
- Where
- 9 sites in France
- Volunteers
- 77 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer of Ovary
Identification and Characterization of Ovarian Cancer and Endometrial Cancer Specific Biomarkers in Vaginal Fluids
The purpose of this study is to: 1. Identification and characterization of ovarian carcinoma well-known biomarkers, carcinoma antigen 125 (CA125) and Human epididymis protein 4 (HE4) and other potential biomarkers in vaginal…
- Trial name
- NCT02704650
- Testing
- fluid sample
- Volunteers
- healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
Triple Negative Breast Cancer, Pancreatic Carcinoma
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with…
- Conditions
- Triple Negative Breast Cancer, Pancreatic Carcinoma, Melanoma, Endometrial Carcinoma
- Trial name
- NCT02807844
- Testing
- MCS110, PDR001
- Where
- 20 sites in United States, Belgium and 9 more
- Volunteers
- 141 people
- Sponsor
- Novartis Pharmaceuticals
Endometrial Cancer, Endometrial Cancer Precursors
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
BACKGROUND: Endometrial cancer is a common and deadly cancer for women. It is getting more common and deadly because risk factors like age and obesity are increasing.
- Conditions
- Endometrial Cancer, Endometrial Cancer Precursors, Ovarian Cancer, Complex Atypical Endometrial Hyperplasia
- Trial name
- DETECT (NCT03538665)
- Where
- United States
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Bladder Carcinoma, Prostate Tumor
Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device
The REMOVE study was an open-label, multicenter validation study on the removal of EpCAM-positive tumor cells from blood collected during tumor surgery using the CATUVAB Kit.
- Conditions
- Bladder Carcinoma, Prostate Tumor, Gallbladder Carcinoma, Endometrial Carcinoma
- Trial name
- REMOVE (NCT06789224)
- Testing
- CATUVAB
- Where
- 6 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Lindis Bloodcare GmbH
Endometrial Cancer
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
A phase 2 study with the primary objective of testing treatment compliance of Upfront Intensity Modulated Proton Beam Therapy (IMPT) and Concurrent Chemotherapy (UPPROACH) for Post-operative Treatment in Loco-regionally Advanced…
- Trial name
- NCT04527900
- Testing
- carboplatin and paclitaxel, pelvic IMPT (Intensity Modulated Proton Therapy)
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Maryland, Baltimore
Endometrial Cancer Stage III, Endometrial Cancer Stage IV
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
- Conditions
- Endometrial Cancer Stage III, Endometrial Cancer Stage IV, Endometrial Cancer Recurrent
- Trial name
- PROMOTE (NCT03621904)
- Testing
- Hormonal Antineoplastics
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Radboud University Medical Center
Endometrial Cancer
Endometrial Cancer - LOHP Alone and With 5FU
To determine the efficacy (response rate [RR], time to progression and survival) of oxaliplatin as a single agent and oxaliplatin in combination with 5 FU in patients with advanced/metastatic endometrial cancer pretreated with…
- Trial name
- NCT00612495
- Testing
- oxaliplatin, 5 FU
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Sanofi
Circulating Tumor DNA, Endometrial Cancer
Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers.
The recent histo-prognostic molecular discoveries of the TCGA (The Cancer Genome Atlas) have shed new light on the classification of endometrial carcinomas.
- Trial name
- NCT04456972
- Testing
- One arm only
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Poitiers University Hospital
Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IV Endometrial Carcinoma
- Trial name
- NCT00095979
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer
Endometrial cancer(EC) is the 4th most common cancer in women globally. Clinicians struggle to determine 'the best' treatment for endometrial cancers as they are very hard to tell apart under the microscope.
- Trial name
- TAPER (NCT04705649)
- Testing
- Treatment de-escalation
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- British Columbia Cancer Agency
Atypical Endometrial Hyperplasia and Endometrial Cancer
Conservative Treatment for Atypical Endometrial Hyperplasia and Early Endometrial Cancer
Exploring the efficacy and pregnancy outcomes of conservative treatment for atypical endometrial hyperplasia and endometrial cancer. Study the factors related to predicting treatment efficacy.
- Trial name
- NCT06170684
- Volunteers
- 100 people
- Sponsor
- Beijing Obstetrics and Gynecology Hospital
Endometrial Hyperplasia Without Atypia, Endometrial Hyperplasia With Atypia
Endometrial Tissues and Mononuclear Cells Receptivity in Pathogenesis of Endometrial Proliferative Processes
A prospective observational study of endometrial tissue and peripheral blood mononuclear cells receptivity to sex steroid hormones in postmenopausal patients with endometrial proliferative processes
- Conditions
- Endometrial Hyperplasia Without Atypia, Endometrial Hyperplasia With Atypia, Endometrial Cancer, Peripheral Blood Mononuclear Cells
- Trial name
- NCT06115577
- Testing
- endometrial tissue and peripheral blood mononuclear cells receptivity
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Pirogov Russian National Research Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.